Hari Ramachandran
Vice President, Technology and Digital Transformation
Expertise:
Hari Ramachandran leads Technology and Digital Transformation for EVERSANA’s Patient Services business unit and is a member of our Digital and Data Councils. He has more than 20 years of experience in the pharmaceutical and healthcare industries, and has held multiple leadership positions across the U.S., UK, Europe and APAC. He is passionate about reimagining patient services processes by leveraging technology, digital, data and analytics; partnerships to transform the patient, provider and caregiver experience; and thus the overall health outcome. He is a member of the Harvard Business Review Advisory Council and presents at seminars and conferences related to patient services and digital transformation.
Articles by Hari Ramachandran
A YEAR OF ACTION: Why Data-Backed, Integrated Commercialization Strategies Are Must-haves in 2022
By applying transformative commercialization models, nurturing digital transformation and trailblazing in global expansion, we can get therapies to patients around the world who are still waiting for treatment options. For the past two years, the pharmaceutical industry has proven that it can adapt to change. In 2020, pharma pivoted to manage the coronavirus pandemic, and […]
The Power to Know When: Balancing High-Tech and High-Touch Solutions to Eliminate Access, Affordability and Adherence Barriers
Forty percent of consumers prefer speaking to a real person on the phone, and for more complex issues, 80% want to speak to a live service agent. In the increasingly virtual world we live in, one thing remains clear: we still crave human interactions. As a result, pharma manufacturers need to understand how patients and […]
Reimagining the SpecialtyRx Patient Journey Through the Lens of a Digital Consumer
Nearly 32% of Americans suffer from complex, chronic or rare conditions, such as autoimmune diseases, genetic disorders or cancer, many of which require a specialty prescription therapy. Despite being only 3% of overall prescriptions, specialty medications represent nearly 50% of the overall prescription drug spend in the U.S. While we have moved to the on-demand […]